Fasudil (Tianjin Chase Sun Pharmaceutical)

N/A

Report date: 2025/01/26 17:36:20
NME

Base Information

Drug NameFasudil (Tianjin Chase Sun Pharmaceutical)
Drug Alias Namefasudil
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho-associated kinases inhibitors
TargetsRho-associated kinases
Therapy Area/IndicationsAngina PectorisPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTianjin Chase Sun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Chase Sun Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAngina PectorisPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A